The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of CDKN2A/b status in pancreatic cancer (PC).
 
Kaitlin Annunzio
No Relationships to Disclose
 
Claire Griffiths
No Relationships to Disclose
 
Igli Arapi
No Relationships to Disclose
 
Matthew Lasowski
No Relationships to Disclose
 
Arun K. Singavi
No Relationships to Disclose
 
Kulwinder Dua
No Relationships to Disclose
 
Abdul H. Khan
No Relationships to Disclose
 
Paul S. Ritch
No Relationships to Disclose
 
Mandana Kamgar
No Relationships to Disclose
 
James P. Thomas
No Relationships to Disclose
 
William Adrian Hall
No Relationships to Disclose
 
Beth Erickson
No Relationships to Disclose
 
Susan Tsai
No Relationships to Disclose
 
Kathleen K. Christians
No Relationships to Disclose
 
Douglas B. Evans
No Relationships to Disclose
 
Raul Urrutia
No Relationships to Disclose
 
Aniko Szabo
No Relationships to Disclose
 
Ben George
Honoraria - Newlink Genetics; Newlink Genetics; Newlink Genetics; Newlink Genetics
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Cook Medical; Cook Medical; Cook Medical; Cook Medical; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Ipsen; Ipsen; Ipsen; Ipsen; Merrimack; Merrimack; Merrimack; Merrimack; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; TERUMO; TERUMO; TERUMO; TERUMO
Research Funding - Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); CeGaT (Inst); CeGaT (Inst); CeGaT (Inst); CeGaT (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Foundation Medicine (Inst); Foundation Medicine (Inst); Foundation Medicine (Inst); Foundation Medicine (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)